Mar. 26 at 10:22 AM
$IPHA Q4 '25 Earnings Results & Recap
• Reported GAAP EPS of -
$0.15
• Reported revenue of
$2.07M down -46.69% YoY
• Innate Pharma anticipates a cash runway until Q3 2026, but its cash and equivalents are insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
